<DOC>
	<DOCNO>NCT01397994</DOCNO>
	<brief_summary>This study determine anti-anginal anti-ischemic effect k-channel opener , nicorandil patient chronic stable angina .</brief_summary>
	<brief_title>Study Assess Efficacy Nicorandil+Atenolol v Atenolol Treatment Chronic Stable Angina .</brief_title>
	<detailed_description>Stress myocardial perfusion imaging ( MPI ) widely use diagnosis risk assessment patient know suspected coronary artery disease ( CAD ) . Also , MPI lend monitoring effect therapeutic intervention anti-ischemic medication , gene therapy , various percutaneous surgical revascularization modality . The effect nitrate , potassium channel activator , calcium-channel blocker , beta-blockers myocardial perfusion image likely attributable change myocardial blood flow myocardial oxygen supply-demand ratio . The major anti-ischemic effect BBs reduction myocardial oxygen consumption rest stress . Beta-blockers decrease myocardial oxygen demand reduction heart rate , blood pressure , myocardial contractility . They also prolong diastole , therefore increase coronary perfusion time . The effect chronic atenolol use dipyridamole SPECT MPI assess randomize , double-blind , crossover study show difference perfusion defect size severity placebo atenolol group whole , although one-third patient large defect atenolol placebo . Bridges et al. , 1992 ( 56 ) Nicorandil , potassium channel activator , give 3 week exhibit significant improvement myocardial perfusion MI angina patient , exercise thallium scan . Yamazaki et al. , 1993 ( 69 ) . Atenolol show cross study affect myocardial perfusion significantly hence combination therapy nicorandil help u determine significant benefit nicorandil MP . Results analyze base line arm difference compare control arm . Guidelines suggest beta blocker first line therapy . To assess anti ischemic effect nicorandil , combination therapy atenolol compare atenolol alone . Since atenolol effect MP insignificant add advantage nicorandil evaluate comparative study . Primary objective ass anti ischemic effect nicorandil . The primary endpoint compare anti ischemic effect 4 week period . Changes perfusion evaluate arm week 4 comparison two study arm make document anti ischemic effect nicorandil . Primary efficacy variable study difference follow endpoint baseline week 4 comparison control study arm use Ex- SPECT MPI . Secondary efficacy variable study difference follow endpoint baseline comparison control study arm use ETT Bruce Protocol week 4 . Secondary objective study evaluate anti anginal effect safety Nicorandil . This open label , randomize control pilot study . Sponsor study Ferozsons Labs . Ltd. All participate patient must sign write informed consent form . Eligible patient proven CAD least one reversible partially reversible myocardial perfusion defect MPI SPECT - Tc-99m functional class I &amp; II CSA , laboratory value within predefined safety limit recruit . Chief exclusion criterion include presence fix perfusion defect , CSA functional class III IV prior revascularization . A total 40 patient enrol study , 20 patient arm ) . Patients randomize 1:1 fashion receive beta blocker combination nicorandil ( experiment arm ) beta blocker ( control arm ) four week unacceptable toxicity , withdrawal consent , whichever come first . Nicorandil dose titrate 10mg bd 7days 20mg bd next 3 week . Concurrent therapy angina attack allow use study medication . All patient treadmill exercise use Bruce protocol . At peak exercise , 10-15 mCi technetium - 99m tetrofosmin inject patient exercise additional 1 2 minutes.. Stress SPECT image acquire begin 15 45 minute completion treadmill stress . At rest 30 mCi technetium-99m tetrofosmin inject SPECT image acquire use protocol . Study monitor centre provide sponsor</detailed_description>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<mesh_term>Atenolol</mesh_term>
	<mesh_term>Nicorandil</mesh_term>
	<criteria>1 . Patients chronic stable angina abnormal Exercise Myocardial Perfusion Spect Scan reversible partially reversible ischemic change . 2 . Male female 3 . Age 25 65 year 4 . Patient must understand willing , able likely comply study procedure restriction comprehends diary card . 5 . Patient must able give voluntary write informed consent . 1 . Hypertension &gt; 170/100 mm Hg 2 . Valvular heart disease cardiomyopathy 3 . Myocardial infarction &lt; 6 month 4 . Unstable angina 5 . Congestive cardiac failure 6 . Severe anemia ( Hb 7G/dl ) 7 . Cardiac arrhythmia II III degree AV block 8 . Significant liver renal dysfunction 9 . IDDM ( Type1 diabetes mellitus ) 10 . Systolic blood pressure &lt; 100 mm Hg 11 . Pregnant nursing woman 12 . Known hypersensitivity nicorandil 13 . On calcium channel blocker 14 . Patients eligible Tc 99m SPECT 15 . Patients beta blocker contraindicate 16 . Geographical inaccessibility treatment followup evaluation</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Nicorandil therapy patient chronic stable angina</keyword>
</DOC>